The organs-on-chips market is expected to reach USD 45.6 million by 2022 from USD 9.6 million in 2017, at a CAGR of 36.6%. The growth of this market is mainly driven by factors such as growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.
The organs-on-chips market is emerging and competitive in nature, with a number of small players competing for market space (including startups firms). Prominent players in this market include Mimetas (Netherlands), Emulate (US), InSphero (Switzerland), Ascendance Bio (US), CN Bio (UK), TissUse (Germany), Kirkstall (UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US). These players have adopted various growth strategies, such as partnerships, acquisitions, agreements, and expansions as well as product launches, to further expand their presence in the global market.
Agreements, collaborations, and partnerships accounted for the largest share of the overall growth strategies followed by key players between 2014 and 2017. Some of the companies that adopted this strategy are CN Bio (UK), Emulate (US), TissUse (Germany), Mimetas (Netherland), and InSphero (Switzerland).
To know about the assumptions considered for the study download the pdf brochure
CN Bio held the leading position in the global organs-on-chips market in 2016. The company offers its products and services for drug discovery and drug safety programs. To enhance its production capabilities and applications, the company focuses on adopting inorganic strategies such as collaborations and agreements. Over the last three years, CN Bio has been a part of six such initiatives that helped the company enhance its presence in this market. For instance, in 2017, CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to predict optimized drug dosing regimens for multi-drug therapies. Furthermore, in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and develop therapeutics for liver diseases and infections by using LiverChip, CN Bio’s human liver-on-a-chip platform.
Emulate is one of the key players in the organs-on-chips market. The company offers organs-on-chips primarily through collaborations with various industry players. For instance, in 2016, Emulate collaborated with LabCorp (US) to incorporate Emulate’s organs-on-chips technology into pre-clinical drug evaluation and testing services. Furthermore, in 2016, Emulate collaborated with Seres Therapeutics (US) to develop an advanced version of Emulate’s Intestine-Chip platform. Such developments enabled the company to expand its presence in the market.
Organs-on-chips Market by Type (Liver, Kidney, Lung, Heart, Intestines, Gut), Offering (Product, Service), Application (Toxicity testing, Physiological model), End User (Academic, Research institute, Pharma companies) - Global Forecast to 2022
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE